Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: A systematic review and meta-analysis

Mazaher Ramezani

Kermanshah University of Medical Sciences

Elisa Zavattaro

Universita degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Medicina Traslazionale

Masoud Sadeghi (✉ sadeghi_mbrc@yahoo.com)

Kermanshah University of Medical Sciences <https://orcid.org/0000-0002-3586-3012>

Research article

Keywords: Psoriasis, psoriatic arthritis, Angiotensin-converting enzyme, polymorphism, meta-analysis

Posted Date: August 15th, 2019

DOI: <https://doi.org/10.21203/rs.2.12915/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at BMC Medical Genetics on January 8th, 2020. See the published version at <https://doi.org/10.1186/s12881-019-0943-3>.

Abstract

Background: Psoriasis is a multifactorial disorder, impacted by both genetic and environmental factors. Herein, a meta-analysis assessed the association of angiotensin-converting enzyme gene insertion/deletion (*ACE* I/D) polymorphism and psoriasis susceptibility. **Methods:** A systematic search was used in databases of PubMed/Medline, Scopus, Web of Science, and Cochrane Library up to January 2019 without language restriction. A dichotomous analysis was carried out by RevMan 5.3 using crude odds ratio (OR) and 95% confidence interval (CI) to investigate the association between *ACE* I/D polymorphisms and the risk of psoriasis. A funnel plot analysis was used by CMA 2.0 to estimate a significant existence of publication bias. **Results:** Out of 61 studies retrieved from the databases, 16 studies were included in the meta-analysis. The pooled ORs for models of D vs. I, DD vs. II, ID vs. II, ID + DD vs. II, and DD vs. II + ID genotypes were 0.96 [95%CI: 0.82, 1.12; P=0.58], 0.99 [95%CI: 0.73, 1.36; P=0.96], 0.78 [95%CI: 0.62, 0.91; P=0.0003], 0.91 [95%CI: 0.73, 1.13; P=0.40], and 1.05 [95%CI: 0.85, 1.30; P=0.68], respectively. A significant difference between *ACE* polymorphisms in patients with/without family history for the disease [OR=1.44; 95%CI: 1.24, 1.67; P<0.001] and also in patients mild/severe psoriasis [OR=0.70; 95%CI: 0.55, 0.88; P=0.002] was identified. **Conclusion:** The results of the meta-analysis showed that *ACE* I/D polymorphism may be associated with psoriasis susceptibility, while ID genotype seemed to have a protective role in Caucasian patients affected by psoriatic arthritis and in studies with hospital-based controls.

Background

Psoriasis is a chronic inflammatory skin disease with unclear etiology that has been correlated with abnormal plasma lipid metabolism and oxidative stress [1], and with a high incidence of cardiovascular diseases [2]. Psoriasis is impacting 2% to 3% of the general population [3]. It is a lifelong disease that may have negative effect on quality of life [4]. The differences in prevalence and incidence show that psoriasis is related to ethnic and geographic variations, being generally more prevalent in the cold northern regions than in the tropical area with a lower prevalence in China and Japan compared to Europe, and is virtually absent in natives of the Andean region of South America [5]. It is a multifactorial disorder, impacted by both genetic and environmental factors and its genetic basis has been established among studies in twins and familial clustering [6]. Angiotensin-converting enzyme (*ACE*) is a zinc metallopeptidase encoded on chromosome 17q23. *ACE* is expressed by skin components like fibroblasts, keratinocytes, and vascular endothelial cells [7]. *ACE* polymorphisms include an insertion (I)/deletion (D) within the intron 16 able to incorporate the most genetic variables responsible for the variability of *ACE* activity in serum, which can be correlated with psoriasis susceptibility [8]. To date, the molecular mechanism of the association between *ACE* I/D polymorphism and psoriasis susceptibility has not fully elucidated [9]. Furthermore, it has been investigated that the use of *ACE* inhibitors can create or aggravate psoriasis in clinical practice [10]. Some studies suggest that *ACE* and its related products might have widespread effects on immune responses and skin inflammation [11]. Some meta-analyses have been previously published on this topic [12-14], unless they did not pay attention to genotypes/allele distribution, quality assessment of the included studies, and did not analyze subgroups of patients according to different factors (i.e. psoriasis variants and ethnicity).

Therefore, the aim of the present meta-analysis was to assess genotypes and alleles distribution in psoriasis based on five genetic models and through the evaluation of studies quality and also considering the association between *ACE* I/D polymorphism and psoriasis susceptibility in case-control studies.

Methods

The study was designed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15].

Identification of eligible studies

A systematic search in PubMed/Medline, Scopus, Web of Science, and Cochrane Library databases was conducted up to January 2019, without language restriction. The search terms or keywords were: “psoriasis”, “psoriatic” and “ACE”, “angiotensin-converting enzyme” and “polymorphism (s)”, “variant (s)”, “gene (s)”. One author (M.S) searched the databases for articles, checked the titles and abstracts of each article, and excluded the not relevant studies. Two authors (M.R and E.Z) reviewed the full-texts to select the studies that met the eligibility criteria. Inclusion criteria were represented by: (1) human case-control study; (2) any subtype of psoriasis (i.e. psoriasis vulgaris, psoriatic arthritis); (3) reporting *ACE* I/D polymorphism in psoriatic patients and controls; and (4) having sufficient data for calculating odds ratio (OR) and 95% confidence interval (95%CI). Exclusion criteria consisted of: (1) animal study; (2) review; (3) meta-analysis; and (4) case report and case series.

Data extraction

The data for each study were extracted by one author (M.S) and consisted of the first author, publication year, genotype frequencies in patients and controls, source of controls (i.e. hospital-based, population-based), psoriasis subtype, genotyping method, p-value for the Hardy–Weinberg Equilibrium (HWE) for controls, ethnicity, gender, family history for psoriasis, age at onset, subtypes of psoriasis, and quality score. Another author (M.R) rechecked the reached data.

Quality assessment

One author (M.R) assessed the quality of each retrieved article using the Newcastle-Ottawa Quality Assessment Scale questionnaire with a maximum total score of 9 for case-control study [16].

Statistical analysis

A dichotomous analysis was carried out by Review Manager 5.3 (RevMan 5.3) using crude OR and 95% CI to indicate the association between *ACE* I/D polymorphisms and psoriasis susceptibility. The association was assessed using five genetic models (allelic, heterozygote, homozygote, dominant, and recessive models) [17]. In addition, within- and between-study variations and heterogeneities were evaluated using Cochran’s Q-statistic: such test considers the null hypothesis in which all studies assessed the same effect (significance level: $P < 0.05$). The effect of heterogeneity was quantified using I^2 statistic to measure the degree of inconsistency across studies, with a range between 0 and 100% that represents the proportion of between-study variability attributable to heterogeneity rather than chance [18]. A statistically significant heterogeneity was obtained with P -value < 0.1 ($I^2 > 50\%$). In case no significant heterogeneity was obtained, fixed-effect model was applied in order to estimate the pooled ORs and CI values. Otherwise, we applied the random-effect model [19]. Chi-square test was used to calculate the HWE in the control groups whether observed genotype frequencies in controls conformed to HWE expectations.

Subgroup analysis was managed according to ethnicity, psoriasis subtype, source of controls and normal HWE. In addition, distributions of alleles and genotypes of *ACE I/D* polymorphism were calculated by IBM SPSS version 22 using binary logistic regression based on some characteristics of psoriatic patients. A funnel plot analysis was used by the Comprehensive Meta-Analysis software version 2.0 (CMA 2.0) using both Egger's and Begg's tests with P-value (two-tailed) <0.05 was estimated as significant existence of publication bias. To evaluate the consistency or stability of the results, the sensitivity analysis was used by removing one study, cumulative analysis, and excluding the studies without HWE in controls.

Results

The schematic representation of the study selection process is shown in **Figure 1**. Out of 61 studies retrieved from the databases after excluding duplicate and not relevant studies, the full-texts of 16 studies were assessed for eligibility. While checking the references of meta-analyses related to this subject, one study had eligibility criteria and therefore its full-text was added. After checking the full-texts, three studies were recognized as meta-analyses and consequently they were excluded. Fourteen studies were included in the systematic-review. Checking the references of meta-analyses, two other studies [20,21] were added that we didn't find their full-text; since they had previously included in other meta-analysis, and since all the required data were extracted from other meta-analyses. In conclusion, 16 studies were included in the meta-analysis.

Study characteristics

Some important characteristics of the studies involved in the present meta-analysis are shown in **Table 1**. The studies were published from 1999 to 2018. Twelve studies reported their research in Caucasian ethnicity [21-32] and four studies [9,20,33,34] in Asian ethnicity. Among Caucasian ethnicity, four studies [23,25,26,31] were conducted in Arab population, four studies [21,24,27,28] enrolled European population, while the remaining four studies [22,29,30,32] evaluated other populations (Pakistani, Iranian and Turkish populations). The meta-analysis included 3003 psoriatic patients and 3689 controls. With regard to the controls source, nine studies [9,20,23-26,32-34] enrolled hospital-based patients, two studies [28,29] were population-based, and five studies [21,22,27,30,31] enrolled controls of unknown origin. In most of the considered studies, the ratio of patients affected by different psoriasis subtypes was not reported [9,20,21,30,32-34], while only 5 and 4 studies were conducted in groups of patients affected predominantly by psoriasis vulgaris [22,24,25,27,31] and psoriatic arthritis [23,26,28,29], respectively. In all studies the used genotyping method was polymerase chain reaction (PCR). In two out of 16 studies, the genotype frequencies of controls [26,27] didn't follow HWE.

Forest plot of the psoriasis susceptibility related to *ACE I/D* polymorphisms based on five genetic models is identified in **Figure 2**. The pooled OR for models of D *versus* I, DD *versus* II, ID *versus* II, ID + DD *versus* II, and DD *versus* II + ID was 0.96 [95%CI: 0.82, 1.12; P=0.58; I²=74% (P_{heterogeneity} (P_h)<0.00001)], 0.99 [95%CI: 0.73, 1.36; P=0.96; I²=71% (P_h<0.0001)], 0.78 [95%CI: 0.62, 0.91; P=0.0003; I²=42% (P_h=0.04)], 0.91 [95%CI: 0.73, 1.13; P=0.40; I²=64% (P_h=0.0003)], and 1.05 [95%CI: 0.85, 1.30; P=0.68; I²=61% (P_h=0.0007)], respectively. Therefore, the presence of ID genotype had a significant slight protective effect against psoriasis development.

Subgroup analysis

The results of psoriasis susceptibility related to *ACE I/D* polymorphisms on the basis of different considered variables are shown in **Table 2**. With regard to ethnicity, the analyses showed that there was no risk of psoriasis related to *ACE I/D* polymorphisms in East Asian populations, but the presence of ID genotype had a slight protective effect against the disease [OR = 0.82; 95%CI: 0.69, 0.97]. Based on three models of DD *versus* II, ID *versus* II, and ID + DD *versus* II the pooled OR was 0.69 (95%CI: 0.52, 0.91), 0.66 (95%CI: 0.50, 0.85), and 0.67 (95%CI: 0.52, 0.86), respectively. Such results showed that DD and ID genotypes had protective roles in psoriatic arthritis, unless this was not valid for psoriasis vulgaris type. The ID genotype had a significantly decreased susceptibility to psoriasis in studies conducted in hospital-based populations based on heterozygote model (OR=0.77, 95%CI: 0.67, 0.90). With regard to the Caucasian population, the ID genotype had a significant protective role in psoriasis if compared with other genotypes in non-Arab and non-European population (other) (OR= 0.73, 95%CI: 0.58, 0.92).

Sensitivity analysis

Out of 16 studies included in the meta-analysis, two studies [26,27] were excluded since P-value of HWE for controls was less than 0.05 (**Table 3**). Notwithstanding, the new analysis showed that the results were unchanged with just a decreased susceptibility to psoriasis among patients carrying ID genotype (OR=0.80, 95%CI: 0.71, 0.90). In addition, other analyses - one study removed and cumulative analysis- didn't change the result of previous overall analysis and therefore they showed the stability of the previous overall result.

Genotype distribution

The alleles and genotypes distribution of *ACE I/D* polymorphism on the basis of the differences in patient's characteristics are shown in Table 4. In detail, only three studies [20-22] considered gender, six studies [9,20,22,23,25,28] reported family history for psoriasis, eight studies [9,22-25,27-29,33] considered the age at the onset, two studies [6,10] reported type of psoriasis, and three studies [31,9,28] reported severity of the disease. The results showed significant difference between *ACE* polymorphisms in patients with family history (familial) *versus* those without family history (sporadic) for the disease [OR=1.44; 95%CI: 1.24, 1.67; P<0.001]. When considering psoriasis severity (grouped among severe or mild disease), a significant difference was obtained [OR=0.70; 95%CI: 0.55, 0.88; P=0.002]. Therefore, the II genotype was significantly more represented in familial patients than in sporadic patients and the DD genotype was more frequent in severe than in mild psoriasis. There was no significant difference in terms of gender, age at the onset, and type of psoriasis among groups of patients.

Quality assessment

The evaluation of quality for each study is shown in **Table 1**. Unfortunately, the full-text of two studies [20,21] was not available for the quality assessment. In detail, ten studies had high quality (score ≥ 7).

Publication bias

We checked publication bias for overall analysis using both Egger's and Begg's tests (**Figure 3**). The results showed that both tests didn't reveal the existence of publication bias between the studies in each model analyses (P>0.05).

Discussion

The present meta-analysis investigated the association between *ACE* I/D polymorphisms with psoriasis susceptibility and also the distribution of genotypes in psoriatic patients. The results indicated the ID genotype is significantly associated with decreased risk of psoriasis development. In addition, in a further subgroup analysis, such genotype resulted to be protective against psoriasis and psoriatic arthritis in Caucasian patients *versus* non-Arab and non-European population. The same genotype showed to be less represented among patients in hospital-based studies. Out of all studies included in the meta-analysis, four studies [9,23,29,32] showed a significant decreased psoriasis susceptibility, while three studies [30,31,34] reported a significant increased risk to develop psoriasis in subjects carrying the D allele. Similarly, the DD genotype was associated to a significant decreased psoriasis susceptibility in four studies [9,24,29,32] and increased risk three studies [30,31,34], respectively. Moreover, the ID genotype showed a significant decreased risk of psoriasis in four studies [9,24,29,33] and a significant elevated susceptibility to the disease in one study [31].

Previously, a meta-analysis conducted in ten studies and checking for the association between *ACE* I/D polymorphisms and psoriasis susceptibility [12] suggested that the ID genotype was a predisposing factor for psoriasis in East Asian subjects. A further meta-analysis evaluated eight studies [13] showed that in Asian ethnicity, the II genotype and I allele were associated with increased susceptibility to psoriasis, whereas the ID genotype seemed to have a protective role. In addition, a meta-analysis enrolling only five studies [14] concluded that only the DD+ID genotype showed significant association with psoriasis (OR=0.75; $P = 0.006$).

The present meta-analysis included 16 studies, and described the different genotypes and alleles' distribution in the groups and subgroups analysis had also been performed. Furthermore, a careful quality assessment of the involved studies had been conducted, in order to consider only the high-quality studies and to provide a further strength to our results.

A possible explanation for its role in psoriasis may be related to the fact that the *ACE* II genotype reduces ACE activity in skin and may prolong or augment activation of the kallikrein–kinin system, thereby increasing the risk for psoriasis [33]. The activation of the kallikrein–kinin system in plasma and tissue has also been associated with psoriasis [36,37]. Several studies indicated that ACE is a major and effective factor in creating angiotensin II (Ang II) and inactivating bradykinin [11,38]. Plasma and tissue ACE levels have been found to be related to the D allele of the *ACE* I/D polymorphism, with DD genotypes having the highest and II genotypes having the lowest ACE activity [39]. Increased levels of serum ACE, IL-6 and IL-8 in psoriasis patients were due to the important role of ACE in inflammation. ACE converts Ang I into Ang II and inactivates bradykinin [40], moreover Ang II activates cytokines like IL-6 and IL-8, thus exerting proinflammatory effects [11]. This shows an important role of ACE in the pathogenesis of psoriasis.

In the previously published data, one study [29] reported the II genotype and I allele frequencies were significantly higher in male patients affected by psoriasis, whereas no association was observed in female patients. It might be supposed that such gender-based discrepancies may be due to differences in the renin-angiotensin system among men and women and the mechanism might involve the role of sex hormones. Another study [22] didn't find any difference between gender and genotype frequencies of *ACE* I/D polymorphism. In addition, no significant difference was found between polymorphisms and age at onset, [9,22-25,28,33] type of psoriasis, [9,29,22] disease severity [9,28], and family history [23,28]. In contrast, the II genotype and I allele frequencies in patients with familial history of psoriasis and type I psoriasis were higher than patients with sporadic psoriasis and type II [22]. Another study [25] confirmed this result in familial psoriasis. Elneam et al. [31] showed that the

DD genotype was more common in case of severe psoriasis vulgaris and the ID was more frequent in non-severe psoriasis vulgaris patients. The present meta-analysis failed to identify a significant difference between gender, age at the onset, and type of psoriasis with genotype frequencies, but the II genotype frequency was significantly higher in patients with positive family history for psoriasis than in sporadic patients; moreover the DD genotype was significantly more represented in subjects with severe than in those with non-severe disease.

The differences between our results and those with other previous studies may be due to diverse factors, thus including racial/geographical difference, number of male/female patients in the considered study and also to the genetic heterogeneity and multifactorial etiology of psoriasis [29]. Also, Ethnic factors and differences among genotyping assay techniques might contribute to the variability between reports evaluating the role of the *ACE* I/D polymorphisms [41]. In our meta-analysis, we have detected that ethnicity, psoriasis subtype, and source of controls can represent significant factors in terms of susceptibility to develop such disease.

Our study presents several important limitations: i) a high heterogeneity among the considered studies was identified; ii) the number of ethnic groups in the studies was limited; iii) in many studies the psoriasis subtypes and source of controls were not clearly specified. Notwithstanding, despite these limitations, there was no publication bias in the analyses.

Conclusions

Summing up, the results of the present meta-analysis showed that *ACE* I/D polymorphisms may be associated with psoriasis susceptibility and, in detail the ID genotype seemed to have a protective role, mainly in Caucasian patients, against psoriatic arthritis, and in the studies considering hospital-based controls. In addition, the DD genotype showed a protective role against psoriatic arthritis. In conclusion, the distributions of genotypes of *ACE* I/D polymorphism were different when the patients were compared in the terms of family history and severity of the disease.

Abbreviations

ACE I/D: Angiotensin-converting enzyme gene insertion/deletion

OR: Odds ratio

CI: Confidence interval

PRISMA: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses

HWE: Hardy–Weinberg Equilibrium

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Authors' Contributions

M.R and M.S: study design, study concept, analysis of images, statistical analysis, data collection, data interpretation, coordination of the study, literature search. E.Z and M.S: critically revised and edited the manuscript before submission and coordination of the study. M.S: drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. [Nemati H, Khodarahmi R, Sadeghi M, Ebrahimi A, Rezaei M, Vaisi-Raygani A](#). Antioxidant status in patients with psoriasis. *Cell Biochem Funct*. 2014;32:268-73.
2. Nemati H, Khodarahmi R, Sadeghi M, Rahmani A, Rezaei M. Serum Lipid Profile in Psoriatic Patients in Kermanshah: A Survey on Vascular Adhesion Protein-1 . *ZJRMS*. 2013;15:8-10.
3. Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. *Br J Dermatol*. 2017;176:650-8.
4. Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Smoking and risk for psoriasis: A population-based twin study. *Int J Dermatol*. 2016;55:72–8.
5. [Chandran V, Raychaudhuri SP](#). Geoeidemiology and environmental factors of psoriasis and psoriatic arthritis. *J Autoimmun*. 2010;34:J314-21.
6. [Gupta R, Debbaneh MG, Liao W](#). Genetic Epidemiology of Psoriasis. *Curr Dermatol Rep*. 2014;3:61-78.
7. Noveral JP, Mueller SN, Levine EM. Release of angiotensin I-converting enzyme by endothelial cells in vitro. *J Cell Physiol* 1987;131:1-5.
8. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest*. 1990;86: 1343-6.

9. Yang K, Zhang F, Li F, Su J, Wen S, Liu Y, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to psoriasis in a Chinese population. *J Renin Angiotensin Aldosterone Syst.* 2014;15:39-43.
10. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. *Dermatologica.* 1990;181:51-3.
11. Scholzen TE, Ständer S, Riemann H, Brzoska T, Luger TA. Modulation of cutaneous inflammation by the angiotensin-converting enzyme. *J Immunol.* 2003;170:3866-73.
12. Xia T, Diao J, Huang H, Li J, Sun L, Li H, et al. Evaluation of the association between CD143 gene polymorphism and psoriasis. *Cell Biochem Biophys.* 2014;70:1617-23.
13. Liu T, Han Y, Lu L. Angiotensin-converting enzyme gene polymorphisms and the risk of psoriasis: a meta-analysis. *Clin Exp Dermatol.* 2013;38:352-8; quiz 359.
14. Song GG, Bae SC, Kim JH, Lee YH. The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis. *J Renin Angiotensin Aldosterone Syst.* 2015;16:195-202.
15. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLOS Medicine*, 2009;6:e1000097.
16. Wells GA, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 12 Jan 2016.
17. Lei S, Huang L, Liu Y, Xu L, Wang D, Yang L. Association between polymorphisms of heat-shock protein 70 genes and noise-induced hearing loss: A meta-analysis. *PLoS One.* 2017;12:e0188539.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21: 1539-58.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials.* 1986; 7:177–88.
20. Liu XH, Zhao SP, Zhao ZQ, Zhao D, Song LY, Yang H. Study on the relationship between insertion/deletion polymorphism of angiotensin-converting enzyme gene with psoriasis. *Chin J Derm Venere.* 2007;21:199–200.
21. Vasku V, Vasku A, Holla L, Kaokova K, Znojil V, Semradova V, et al. Interaction of five gene polymorphisms at psoriasis. *J Invest Derm.* 1999;113:494.
22. Ozkur M, Erbagci Z, Nacak M, Tuncel AA, Alasehirli B, Aynacioglu AS. Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with psoriasis. *Br J Dermatol.* 2004;151:792-5.
23. Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. *Rheumatol Int.* 2007;27:1119-23.
24. Weger W, Hofer A, Wolf P, El-Shabrawi Y, Renner W, Kerl H, et al. The angiotensin-converting enzyme insertion/deletion and the endothelin -134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis. *Exp Dermatol.* 2007;16:993-8.
25. Nagui NA, Abdel Hay RM, Rashed L. Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and the risk for psoriasis. *J Egypt Women Dermatol Soc.* 2012;9:14–7.
26. Shehab DK, Al-Jarallah KF, Al-Awadhi AM, Al-Herz A, Nahar I, Haider MZ. Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondylarthropathies. *J Biomed Sci.*

2008;15:61-7.

27. Veletza S, Karpouzis A, Giassakis G, Caridha R, Papaioakim M. Assessment of insertion/deletion polymorphism of the angiotensin converting enzyme gene in psoriasis. *J Dermatol Sci*. 2008;49:85-7.
28. Coto-Segura P1, Alvarez V, Soto-Sánchez J, Morales B, Coto E, Santos-Juanes J. Lack of association between angiotensin I-converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain. *Int J Dermatol*. 2009;48:1320-3.
29. Munir S, Rahman SB, Rehman S, Saba N, Torinsson Naluai Å, Agha H, et al. The angiotensin-converting enzyme gene insertion polymorphism: a higher risk for psoriasis in male patients. *Br J Dermatol*. 2016;175:824-6.
30. Agha Z, Arzoo Shaiq P, Ahmed S, Ali L, Azam M, Benish Ali SH, et al. A study of ACE, eNOS and MTHFR association with psoriasis in Pakistani population. *Meta Gene*. 2018;15:65-9.
31. Elneam AIA, Al-Dhubaibi MS, Alrheam AIAA. Angiotensin-Converting Enzyme (ACE) D Allele as a Risk Factor for Increase Serum Interleukin-6 and Interleukin-8 in Psoriasis Patients. *Open Access Maced J Med Sci*. 2018;6:772-6.
32. Tanhapour M, Falahi B, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, et al. Angiotensin-converting enzyme insertion/deletion (rs106180) and angiotensin type 1 receptor A1166 C (rs106165) genotypes and psoriasis: Correlation with cellular immunity, lipid profile, and oxidative stress markers. *J Cell Biochem*. 2018.
33. Chang YC, Wu WM, Chen CH, Lee SH, Hong HS, Hsu LA. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. *Br J Dermatol*. 2007;156:642-5.
34. Huang M, Huang G-D, Peng D. Angiotensin-converting enzyme I/D polymorphism and susceptibility of psoriasis. *Biomed Res*. 2017;28:5450-3.
35. Ku SH, Kwon WJ, Cho EB, Park EJ, Kim KH, Kim KJ. The association between Psoriasis Area and Severity Index and cardiovascular risk factor in Korean psoriasis patients. *Ann Dermatol*. 2016;23:360-63.
36. Winkelmann RK. Total plasma kininogen in psoriasis and atopic dermatitis. *Acta Derm Venereol (Stockh)*. 1984;64:261-3.
37. Poblete MT, Reynolds NJ, Figueroa CD, Burton JL, Muller-Esterl W, Bhoola KD. Tissue kallikrein and kininogen in human sweat glands and psoriatic skin. *Br J Dermatol*. 1991;124:236–41.
38. Jin SY, Park HH, Li GZ, Lee HJ, Hong MS, Hong SJ, et al. Association of Angiotensin Converting Enzyme Gene I/D Polymorphism of Vitiligo in Korean Polymorphism. *Pigment Cell Res*. 2004;17:84–6.
39. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. *Biochem J*. 1993;290:33–40.
40. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. *Biochemistry*. 1989;28:5311–8.
41. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffery S, et al. Angiotensin converting enzyme insertion/deletion polymorphism: association with ethnic origin. *J Hypertens* 1994;12:955-7.

Tables

Table 1: Characteristics of the studies included in the meta-analysis (n=16)

Genotyping												
Study, year	Ethnicity	Psoriasis			Control			Source of controls	Subtype of psoriasis	Genotyping method	P-value for HWE for controls	Score*
		II	ID	DD	II	ID	DD					
Vasku, 1999 [21]	Caucasian (European)	40	111	49	45	104	59	Unknown	Unknown	PCR	0.947	NA
Ozkur, 2004 [22]	Caucasian (Turkish)	12	40	34	28	69	57	Unknown	Vulgaris (94.2%)	PCR	0.378	7
Al-Awadhi, 2007 [23]	Caucasian (Arab)	7	19	25	14	45	41	Hospital-based	Arthritis	PCR	0.770	8
Chang, 2007 [33]	Asian	172	108	32	287	265	63	Hospital-based	Unknown	PCR	0.873	7
Liu, 2007 [20]	Asian	31	38	19	23	48	24	Hospital-based	Unknown	PCR	0.917	NA
Weger, 2007 [24]	Caucasian (European)	61	92	54	35	93	54	Hospital-based	Vulgaris	PCR	0.653	7
Nagui, 2012 [25]	Caucasian (Arab)	9	13	8	6	8	6	Hospital-based	Vulgaris	PCR	0.371	8
Shehab, 2008 [26]	Caucasian (Arab)	2	2	9	19	18	74	Hospital-based	Arthritis	PCR	<0.001	6
Veletza, 2008 [27]	Caucasian (European)	2	11	14	5	7	15	Unknown	Vulgaris	PCR	0.038	7
Coto-Segura, 2009 [28]	Caucasian (European)	38	124	106	34	145	93	Population-based	Arthritis	PCR	0.050	6
Yang, 2014 [9]	Asian	350	269	49	304	299	65	Hospital-based	Unknown	PCR-RFLP	0.491	7
Munir, 2016 [29]	Caucasian (Pakistani)	118	239	129	88	299	184	Population-based	Arthritis (92%)	PCR	0.063	6
Huang,	Asian	55	71	35	119	111	26	Hospital-	Unknown	PCR	0.987	6

2017 [34]									based			
Agha, 2018 [30]	Caucasian (Pakistani)	72	87	74	90	122	51	Unknown	Unknown	PCR	0.405	6
Elneam, 2018 [31]	Caucasian (Arab)	18	33	22	22	17	8	Unknown	Vulgaris	PCR	0.157	7
Tanhapour, 2018 [32]	Caucasian (Iranian)	16	57	27	8	50	42	Hospital-based	Unknown	PCR-RFLP	0.191	6

*Abbreviations: PCR, Polymerase chain reaction; RFLP, restriction fragment length polymorphism. *Based on the Newcastle-Ottawa Quality Assessment Scale*

Table 2: Analysis of psoriasis susceptibility related to angiotensin-converting enzyme insertion/deletion (I/D) polymorphism based on the studies with normal Hardy-Weinberg Equilibrium when considering controls, ethnicity, psoriasis subtype, controls source, Caucasian population

Variable (no. of study)	D vs. I	DD vs. II	ID vs. II	ID + DD vs. II	DD vs. II + ID
	OR (95%CI), I ²	OR (95%CI), I ²	OR (95%CI),	OR (95%CI), I ²	OR (95%CI), I ²
	(%), P _h	(%), P _h	I ² (%), P _h	(%), P _h	(%), P _h
Overall (16)	0.96 (0.82, 1.12), 74, <0.00001	0.99 (0.73, 1.36), 71, <0.00001	0.81 (0.72, 0.91), 42, 0.04	0.91 (0.73, 1.13), 64, 0.0003	1.05 (0.85, 1.30), 61, 0.0007
Ethnicity					
East Asian (4)	0.95 (0.68, 1.32), 86, <0.0001	0.99 (0.51, 1.93), 84, 0.0004	0.82 (0.61, 1.10), 63, 0.05	0.86 (0.59, 1.25), 79, 0.003	1.09 (0.65, 1.84), 77, 0.005
Caucasian (12)	0.96 (0.79, 1.17), 70, 0.0001	0.99 (0.68, 1.45), 67, 0.0005	0.82 (0.69, 0.97), 39, 0.08	0.95 (0.71, 1.27), 59, 0.004	1.03 (0.81, 1.32), 57, 0.007
Psoriasis subtype					
Arthritis (4)	0.83 (0.61, 1.12), 66, 0.03	0.69 (0.52, 0.91), 49, 0.12	0.66 (0.50, 0.85), 0, 0.78	0.67 (0.52, 0.86), 8, 0.35	1.04 (0.73, 1.48), 53, 0.09
Vulgaris (5)	1.12 (0.77, 1.65), 65, 0.02	1.29 (0.62, 2.68), 63, 0.03	1.19 (0.65, 2.21), 60, 0.04	1.29 (0.64, 2.63), 71, 0.009	1.02 (0.76, 1.37), 0, 0.48
Source of controls					
Hospital-based (9)	0.84 (0.68, 1.04), 72, 0.0004	0.84 (0.55, 1.29), 68, 0.002	0.77 (0.67, 0.90), 23, 0.24	0.80 (0.61, 1.04), 56, 0.02	0.97 (0.71, 1.32), 58, 0.01
Others (7)	1.12 (0.88, 1.42), 77, 0.0003	1.22 (0.74, 2.01), 77, 0.0002	1.00 (0.72, 1.40), 59, 0.02	1.11 (0.75, 1.64), 72, 0.001	1.14 (0.83, 1.56), 68, 0.005
Caucasian population					
Arab (4)	1.04 (0.52, 2.06), 75, 0.008	1.65 (0.91, 3.00), 2, 0.38	1.43 (0.81, 2.53), 0, 0.47	1.56 (0.93, 2.62), 7, 0.36	1.41 (0.89, 2.23), 0, 0.68
Europe (4)	0.94 (0.81, 1.10), 21, 0.28	0.85 (0.62, 1.16), 18, 0.30	0.84 (0.63, 1.12), 47, 0.13	0.84 (0.64, 1.10), 48, 0.13	0.99 (0.79, 1.24), 4, 0.37
Other (Iran, Pakistan, and Turkey) (4)	0.93 (0.64, 1.34), 85, 0.0001	0.83 (0.38, 1.84), 86, <0.0001	0.73 (0.58, 0.92), 41, 0.17	0.82 (0.49, 1.36), 75, 0.007	0.97 (0.57, 1.66), 84, 0.0003

* Bold number means significant (P<0.05). P_h equals to P_{heterogeneity}

Table 3: Analysis of psoriasis susceptibility related to angiotensin-converting enzyme insertion/deletion (I/D) polymorphism after excluding the studies without normal Hardy-Weinberg Equilibrium

Variable	D vs. I	DD vs. II	ID vs. II	ID + DD vs. II	DD vs. II + ID
(no. of study)	OR (95%CI), I ² (%), P _h	OR (95%CI), I ² (%), P _h	OR (95%CI), I ² (%), P _h	OR (95%CI), I ² (%), P _h	OR (95%CI), I ² (%), P _h
Normal	0.95 (0.80, 1.12),	0.97 (0.70, 1.34),	0.80 (0.71, 0.90),	0.89 (0.72, 1.11),	1.05 (0.84, 1.32),
HWE (14)	78, <0.00001	74, <0.00001	47, 0.03	67, 0.0002	66, 0.0002

* Bold number means significant (P<0.05). P_h equals to P_{heterogeneity}

Table 4: Distribution of alleles and genotypes of angiotensin-converting enzyme insertion/deletion (I/D) polymorphism with respect to patient characteristics in psoriasis

Variable (no. of study)	II	ID	DD	I	D	OR (95%CI), P-value
Sex (3)						
Male (n=194) vs.	41 (21%) vs.	102 (53%) vs.	51 (26%) vs.	184 (47.4%)	204 (52.6%)	0.99 (0.74,
Female (n=180)	42 (23%)	87 (49%)	51 (28%)	vs. 171 (47.5%)	vs. 189 (52.5%)	1.33), 0.983
Family history (6)						
Positive (n=506) vs.	224 (44%) vs.	194 (38%) vs.	88 (18%) vs.	642 (63.4%)	370 (36.6%)	1.44 (1.24,
Negative (n=685)	223 (32%)	308 (45%)	154 (22%)	vs. 754 (55%)	vs. 616 (45%)	1.67), <0.001
Age at onset (9)						
Early-onset (n=1522)	516 (33.9%)	666 (43.8%)	340 (22.3%)	1698 (55.8%)	1346 (44.2%)	0.93 (0.82,
vs. Late-onset (n=715)	vs. 265 (37.1%)	vs. 298 (41.7%)	vs. 152 (21.2%)	vs. 828 (57.9%)	vs. 602 (42.1%)	1.04), 0.208
Type of psoriasis (2)						
Type I (n=256) vs.	151 (59%) vs.	90 (35.2%)	15 (5.8%) vs.	392 (76.6%)	120 (23.4%)	1.31 (0.99,
Type II (n=204)	109 (53.4%)	vs. 71 (34.8%)	24 (11.8%)	vs. 289 (71%)	vs. 119 (39%)	1.74), 0.060
Severity (3)						
Mild (n=807) vs.	332 (41.1%)	355 (44%) vs.	120 (14.9%)	1019 (63.1%)	595 (36.9%)	0.70 (0.55,
Severe (n=202)	vs. 74 (36.6%)	71 (35.1%)	vs. 57 (28.2%)	vs. 219 (54.2%)	vs. 185 (45.8%)	0.88), 0.002

* Bold number means significant ($P < 0.05$); *vs.* = *versus*; Early-onset = age at onset ≤ 40 years; Late-onset = age at onset > 40 years; Type I = having a positive family history and early-onset disease; Type II = having a negative family history and late-onset disease; Mild severity = PASI < 10 ; Severe psoriasis = PASI ≥ 10 [PASI = Psoriasis Area and Severity Index] [35].

Figures

Figure 1

Flow-chart of the study

Figure 2

Forest plot of psoriasis susceptibility related to angiotensin-converting enzyme insertion/deletion (I/D) polymorphism based on five genetic models: (a) D vs. I, (b) DD vs. II, (c) ID vs. II, (d) ID + DD vs. II, and (e) DD vs. II + ID

Figure 3

Funnel plot of the risk of psoriasis related to angiotensin-converting enzyme insertion/deletion (I/D) polymorphism based on five genetic models